Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00292552 · ClinicalTrials.gov registry record
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 2,747
- Enrollment target
NCT00292552 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 2,747 participants.
The verdict
NCT00292552 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 2,747 participants
- Enrollment target
Study Summary
This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.
Interventions
- OTHER Novel endpoint determination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,747 participants |
| Start Date | 2005-12 |
| Est. Completion | 2010-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00292552
The ClinicalTrials.gov registry entry for NCT00292552 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,747 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Novel endpoint determination is the first listed.
NCT00292552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00292552 about?
NCT00292552 is a clinical study titled "Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints". This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects ...
What is the current status of trial NCT00292552?
This trial is currently completed. The enrollment target is 2,747 participants. The study started on 2005-12. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00292552?
The interventions under investigation include: Novel endpoint determination (OTHER).
Who is sponsoring clinical trial NCT00292552?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.